Vertex Names Autoimmune Lead Drug
Vertex Pharmaceuticals has named VX-497 as its lead drug candidate for the treatment of autoimmune diseases following a two-year program.
VX-497 is an orally-administered inosine monophosphate dehydrogenase inhibitor which is currently in preclinical trials and has the potential to treat psoriasis, asthma, rheumatoid arthritis, systemic lupus erythematosus and organ transplant rejection, says the company. However, the company initially intends to develop VX-497 for a psoriasis indication.
According to David Armistead, senior scientist at the company, VX-497 is "an impressive drug candidate with a tolerability and efficacy profile in the laboratory that is potentially suitable for use in chronic autoimmune diseases."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze